The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN

The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its cognate tyrosine kinase. Paradoxically, although...

Descripción completa

Detalles Bibliográficos
Autores principales: Spivak, Jerry L., Moliterno, Alison R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987816/
https://www.ncbi.nlm.nih.gov/pubmed/33777803
http://dx.doi.org/10.3389/fonc.2021.641613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987816/
https://www.ncbi.nlm.nih.gov/pubmed/33777803
http://dx.doi.org/10.3389/fonc.2021.641613

Ejemplares similares